Determining the Effect of Antibiotic Drop Prophylaxis on the Conjunctival Flora
Ranibizumab (Lucentis) is currently the best treatment for wet Age-Related Macular Degeneration (AMD). To work, the drug must be injected by means of an intravitreal injection (IVT) into the vitreous (jelly-like material) cavity in the back of the eye, repeatedly at intervals ranging from one to several months. Endophthalmitis is a rare but devastating infection of the eye that occurs in approximately 0.2% of patients after IVT injection. Many ophthalmologists ask patients to use antibiotic eye drops after IVT injection in the hope that this may reduce the risk of endophthalmitis. There is no proof that this happens and there is a possible risk that repeated exposure to the same antibiotic may cause antibiotic resistance organisms (bacteria) to develop over time.
The investigators hypothesize that repeated exposure to antibiotic during the initial stages of treatment for AMD will result in a progressive shift in the conjunctival flora with an increasing number of antibiotic resistant organisms appearing over time. If this is demonstrated, changes to the prevailing treatment approach will be needed to reduce the long term risk of a patient developing antibiotic resistant endophthalmitis during treatment.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Intraocular injection of a VEGF inhibitor on a repeated basis has become the standard of care for the treatment of Age-Related Macular Degeneration (AMD) following pivotal studies which demonstrated that vision could be stabilized in 90% of treated patients. Most patients require injection, on average, every two months indefinitely.
The incidence of intraocular infection (endophthalmitis) following intraocular injection is approximately 0.2%. Current injection protocols involve the use of topical poviodine prior to injection based on evidence that this significantly reduces the bacterial flora on the conjunctiva. Following injection there is often some reflux of vitreous fluid from the cavity of the eye into the subjunctival space. For this reason many Ophthalmologists have patients use topical antibiotics for 2-3 days post injection with the expectation that this may reduce the risk of infection as the eye is healing.
Ta et al have demonstrated that following a 3 day course of topical antibiotic the incidence of resistant strains of bacteria in the conjunctival sac does not significantly increase (159 patients).There are no longitudinal studies which examine the effects of repeated short term antibiotic exposure on the conjunctival flora over time.
This is a prospective, randomized, comparative study which will follow the conjunctival flora of patients undergoing induction treatment with a VEGF inhibitor for AMD. The incidence of resistant organisms in the group receiving antibiotics will be compared to that in a similar group who do not receive antibiotics. Following informed consent, patients will have a conjunctival swab taken by the treating Ophthalmologist after instillation of sterile topical anesthetic but before application of poviodine. The swabs will be cultured in thyoglycollate broth. Bacteria present and resistance to the antibiotic used will be identified. This process will be repeated each visit during the induction phase of treatment which consists of four sequential injections each a month apart.
Patients in the antibiotic arm will be asked to use topical Moxifloxacin drops 4 times a day for 3 days following injection. The control group will not receive antibiotics.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Ontario
-
London, Ontario, Canadá, N6A 4V2
- Ivey Eye Institute, St. Joseph's Health Care Centre
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- all patients undergoing their first ever injection to treat AMD and who are expected to continue treatment in London for at least the next 3 injections are potentially eligible.
- able to provide Informed Consent.
Exclusion Criteria:
- current contact lens use.
- use of topical antibiotics in the study eye in the preceding 6 months.
- patients in whom eye surgery in the study eye is anticipated in the next 4 months.
- documented allergy to the drug or vehicle.
- patients with active ocular, periocular or systemic infection.
- immunosuppressed patients.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Moxifloxacin 0.5%
1 drop four times daily for 3 days in affected eye post intravitreal injection
|
1 drop 4 times daily times 3 days post ranibizumab intravitreal injection
Outros nomes:
|
|
Sem intervenção: No antibiotic use
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence of antibiotic resistant organisms
Prazo: 4 months
|
Conjunctival culture will be obtained in the designated "study" eye prior to the first intravitreal injection in de novo AMD patients and will be repeated prior to the next 3 injections. Susceptibility or resistance of the ocular surface flora to Moxifloxicin will be assessed by standard micro analysis. |
4 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Philip L Hooper, MD, FRCSC, Ivey Eye Institute, St. Joseph's Health Care Centre
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- R-10-458
- 17354 (Outro identificador: REB)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Moxifloxacin 0.5%
-
RSP Systems A/SConcluídoDiabetes MellitusAlemanha
-
RSP Systems A/SConcluídoDiabetes MellitusAlemanha
-
RSP Systems A/SConcluído
-
RSP Systems A/SRetiradoDiabetes MellitusDinamarca, Alemanha, Suécia, Reino Unido
-
Mayo ClinicInscrevendo-se por convite
-
Chong Kun Dang PharmaceuticalConcluídoDiabetes tipo 2Coréia do Sul
-
Azienda Sanitaria Locale ASL 6, LivornoAinda não está recrutandoInsuficiência Venosa | Tromboembolismo Venoso (TEV) | Síndrome pós-trombótica | Trombose Venosa Profunda (Membros)
-
Beijing Tiantan HospitalAinda não está recrutandoDorme | Bloqueio Gânglio Estrelado | Distúrbios Prolongados da ConsciênciaChina
-
National Institute of Hygiene and Epidemiology,...Ministry of Health, Vietnam; Ministry of Science and Technology, VietnamConcluído
-
Harrow IncInscrevendo-se por conviteOclusão da veia da retina | Degeneração Macular Relacionada à Idade (DMRI) | Edema macular diabético (EMD) | Retinopatia Diabética (RD)Estados Unidos